FDA Removes Clinical Hold on Nomlabofusp Study for Friedreich’s Ataxia
Three years after the U.S. Food and Drug Administration (FDA) first placed a full clinical hold on Larimar Therapeutics’ Phase 2 clinical study, the hold has officially been lifted. The…